These symptoms can easily be mistaken for side effects of the GLP-1 medication itself, leading to mismanagement
But these changes are often mild enough to question whether they are real or just expectation bias
Currently, common clinical GLP-1RAs include exenatide and exenatide-LAR [34,35,36,37,38,39,40], lixisenatide [41,42,43,44], beinaglutide [45], liraglutide [46,47,48,49,50,51,52,53], semaglutide [54,55,56,57,58], albiglutide [59,60,61], dulaglutide [62,63,64], oral semaglutide [58, 65,66,67], PEG-loxenatide [68] and tirzepatide [68,69,70,71,72,73] (Table 1)
We used inverse-probability-of-censoring weights to address differential follow-up, and stabilized censoring weights were well behaved (few extremes), which helps explain why the confidence intervals are not excessively wide
The data reveals patterns so consistent they appear in roughly 85% of patients who complete treatment
This timeframe allows your body to adapt and reveals whether your current dose produces adequate appetite suppression or whether progression to a higher dose would better support your goals